SG11201604501TA - Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer - Google Patents
Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancerInfo
- Publication number
- SG11201604501TA SG11201604501TA SG11201604501TA SG11201604501TA SG11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA
- Authority
- SG
- Singapore
- Prior art keywords
- estrogen receptor
- treatment
- breast cancer
- locally advanced
- positive breast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361913167P | 2013-12-06 | 2013-12-06 | |
US201461981672P | 2014-04-18 | 2014-04-18 | |
PCT/IB2014/002679 WO2015082990A1 (en) | 2013-12-06 | 2014-12-05 | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201604501TA true SG11201604501TA (en) | 2016-07-28 |
Family
ID=52347358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201604501TA SG11201604501TA (en) | 2013-12-06 | 2014-12-05 | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
Country Status (12)
Country | Link |
---|---|
US (2) | US9675586B2 (ko) |
EP (1) | EP3089747A1 (ko) |
JP (1) | JP2016540767A (ko) |
KR (1) | KR20160085915A (ko) |
CN (1) | CN105916501A (ko) |
AU (1) | AU2014358850A1 (ko) |
CA (1) | CA2932106A1 (ko) |
HK (1) | HK1223557A1 (ko) |
IL (1) | IL245758A0 (ko) |
MX (1) | MX2016007282A (ko) |
SG (1) | SG11201604501TA (ko) |
WO (1) | WO2015082990A1 (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
SI3305285T1 (sl) | 2012-09-26 | 2021-03-31 | Aragon Pharmaceuticals, Inc. | Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka |
US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
KR20160021277A (ko) | 2013-06-19 | 2016-02-24 | 세라곤 파마슈티컬스, 인크. | 에스트로겐 수용체 조절제 및 이의 용도 |
JP6389517B2 (ja) | 2013-06-19 | 2018-09-12 | セラゴン ファーマシューティカルズ, インク. | アゼチジンエストロゲン受容体調節因子及びその使用 |
BR112016020953A2 (pt) | 2014-03-13 | 2018-01-23 | Hoffmann La Roche | composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção |
US20180173846A1 (en) * | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
EP3180316A1 (en) | 2014-08-11 | 2017-06-21 | F. Hoffmann-La Roche AG | Crystalline forms of an estrogen receptor modulator |
EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
WO2016097072A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
CN107531722B (zh) | 2015-05-26 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 杂环雌激素受体调节剂及其用途 |
CN108137511A (zh) | 2015-10-07 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 制备(e)-3-(4-((e)-2-(2-氯-4-氟苯基)-1-(1h-吲唑-5-基)丁-1-烯-1-基)苯基)丙烯酸的方法 |
KR102099159B1 (ko) | 2015-11-12 | 2020-04-10 | 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 | 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법 |
CN113717170A (zh) | 2016-04-01 | 2021-11-30 | 里科瑞尔姆Ip控股有限责任公司 | 雌激素受体调节剂 |
US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
WO2018234778A1 (en) * | 2017-06-20 | 2018-12-27 | The Institute Of Cancer Research: Royal Cancer Hospital | METHODS AND MEDICAL USES |
GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
JOP20200076A1 (ar) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals Inc | مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال |
EP3498273A1 (en) * | 2017-12-14 | 2019-06-19 | Universität Wien | Pharmaceutical composition for modulating the response of a gaba-a receptor |
EP3787632B1 (en) * | 2018-05-02 | 2022-05-25 | Estetra SPRL | Treatment regimen for the treatment of advanced oestrogen receptor positive breast cancer |
KR102682985B1 (ko) | 2018-06-21 | 2024-07-10 | 에프. 호프만-라 로슈 아게 | 3-((1R,3R)-1-(2,6-다이플루오로-4-((1-(3-플루오로프로필)아제티딘-3-일)아미노)페닐)-3-메틸-1,3,4,9-테트라하이드로-2H-피리도[3,4-b]인돌-2-일)-2,2-다이플루오로프로판-1-올의 고체 형태, 치환된 페닐 또는 피리딘일 잔기를 포함하는 융합된 삼환형 화합물의 제조 방법, 및 이의 사용 방법 |
MX2021002666A (es) | 2018-09-07 | 2021-07-16 | Sanofi Sa | Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo. |
JP2022531898A (ja) * | 2019-05-09 | 2022-07-12 | サノフイ | 転移性または進行性乳房がん患者において使用するための6-(2,4-ジクロロフェニル)-5-[4-[(3s)-1-(3-フルオロプロピル)ピロリジン-3-イル]オキシフェニル]-8,9-ジヒドロ-7h-ベンゾ[7]アヌレン-2-カルボン酸 |
WO2020238733A1 (zh) | 2019-05-24 | 2020-12-03 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物的晶型及其制备方法和用途 |
US11278532B2 (en) | 2019-08-06 | 2022-03-22 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
PE20142461A1 (es) | 2012-03-20 | 2015-02-05 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno y sus usos |
US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
-
2014
- 2014-12-05 AU AU2014358850A patent/AU2014358850A1/en not_active Abandoned
- 2014-12-05 JP JP2016536557A patent/JP2016540767A/ja active Pending
- 2014-12-05 SG SG11201604501TA patent/SG11201604501TA/en unknown
- 2014-12-05 CA CA2932106A patent/CA2932106A1/en not_active Abandoned
- 2014-12-05 KR KR1020167017951A patent/KR20160085915A/ko not_active Application Discontinuation
- 2014-12-05 EP EP14827261.0A patent/EP3089747A1/en not_active Withdrawn
- 2014-12-05 US US14/561,701 patent/US9675586B2/en not_active Expired - Fee Related
- 2014-12-05 MX MX2016007282A patent/MX2016007282A/es unknown
- 2014-12-05 CN CN201480066547.XA patent/CN105916501A/zh active Pending
- 2014-12-05 WO PCT/IB2014/002679 patent/WO2015082990A1/en active Application Filing
-
2016
- 2016-05-22 IL IL245758A patent/IL245758A0/en unknown
- 2016-10-14 HK HK16111865.1A patent/HK1223557A1/zh unknown
-
2017
- 2017-05-08 US US15/589,391 patent/US10034860B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2015082990A1 (en) | 2015-06-11 |
AU2014358850A8 (en) | 2016-08-04 |
CN105916501A (zh) | 2016-08-31 |
US20150157606A1 (en) | 2015-06-11 |
EP3089747A1 (en) | 2016-11-09 |
US20170239219A1 (en) | 2017-08-24 |
HK1223557A1 (zh) | 2017-08-04 |
US10034860B2 (en) | 2018-07-31 |
MX2016007282A (es) | 2016-09-07 |
IL245758A0 (en) | 2016-07-31 |
US9675586B2 (en) | 2017-06-13 |
JP2016540767A (ja) | 2016-12-28 |
CA2932106A1 (en) | 2015-06-11 |
KR20160085915A (ko) | 2016-07-18 |
AU2014358850A1 (en) | 2016-06-16 |
WO2015082990A8 (en) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1223557A1 (zh) | 用於治療局部晚期或轉移性雌激素受體陽性乳腺癌的雌激素受體調節劑 | |
HUS2400002I1 (hu) | Mellrák kezelése szelektív ösztrogénreceptor-módosítók alkalmazásával | |
IL237558A0 (en) | Methods for treating locally advanced breast cancer | |
IL245196A0 (en) | Antibodies against cd38 for the treatment of human cancers | |
IL245731A0 (en) | Combined treatment for cancer | |
HUE057061T2 (hu) | Kombinációs terápia rák kezelésére | |
EP2968343A4 (en) | POLY THERAPY FOR TREATING CANCER | |
HK1222869A1 (zh) | 用於治療癌症的針對 的偶聯抗體 | |
HK1222548A1 (zh) | 治療惡性腫瘤的藥物組合 | |
HK1219737A1 (zh) | 用於治療癌症的新化合物 | |
HK1213909A1 (zh) | 通過調節 治療乳腺癌 | |
IL281541A (en) | Specific anti-cd38 antibodies for treating human cancers | |
HK1223547A1 (zh) | 癌症治療方法 | |
IL245551A0 (en) | Anti-matriptase antibodies for cancer treatment | |
PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
EP3077812A4 (en) | Methods for the prognosis of breast cancer | |
GB201321531D0 (en) | Treatment for cancers | |
AP2015008905A0 (en) | Novel compounds for the treatment of cancer | |
GB201300546D0 (en) | Cancer Treatment |